Veradermics, a UK-based biopharmaceutical company, has seen its shares surge by 9% following positive trial results for its new hair loss treatment. The treatment, which is currently in its final stages of development, has shown significant improvements in hair growth and reduction of hair loss in patients.
According to the company, the trial results were based on a study involving 200 patients with moderate to severe hair loss. The participants were randomly assigned to receive either the treatment or a placebo, and the results showed that those receiving the treatment experienced a 35% increase in hair growth and a 25% reduction in hair loss.
The company's shares rose 9% on the FTSE 250 index, with the company's market capitalisation increasing to £1.2 billion. The positive trial outcome is expected to increase the company's valuation and make it an attractive acquisition target for pharmaceutical companies.
The treatment is expected to enter the market in the coming years, with the company planning to submit its application for regulatory approval in the near future. The company has not disclosed any information on the potential pricing of the treatment.
The positive trial results have been welcomed by investors, who believe that the treatment has the potential to become a leading product in the hair loss market. The company's shares are expected to continue to rise in the coming weeks and months, as more investors become aware of the treatment's potential.